TY - JOUR AU - Thronicke, Anja AU - Steele, Megan L. AU - Grah, Christian AU - Matthes, Burkhard AU - Schad, Friedemann PY - 2017 DA - 2017/12/13 TI - Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer JO - BMC Complementary and Alternative Medicine SP - 534 VL - 17 IS - 1 AB - Despite improvement of tumour response rates in patients with progressive and metastatic cancer, immune checkpoint inhibitors (ICM) induce toxicities in cancer patients. Viscum album L. (VA, mistletoe) extracts are applied as add-on cancer therapy especially in German speaking countries and within integrative and anthroposophical concepts with the goal to improve quality of life. The primary objective of this pilot observational cohort study was to determine the rate of adverse events (AE) related to ICM therapy with and without VA in patients with advanced or metastatic cancer in a certified Cancer Center. SN - 1472-6882 UR - https://doi.org/10.1186/s12906-017-2045-0 DO - 10.1186/s12906-017-2045-0 ID - Thronicke2017 ER -